TNF Processing in Pulmonary Immunopathology
TNF Processing in Pulmonary Immunopathology
批准号:
7667199
负责人:
RICHARD I ENELOW
金额:
$35.73万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-09-15 至 2012-08-31
关键词:
Adoptive TransferAlveolarAlveolar CellAnimalsAntigensBlood capillariesCD8B1 geneCXC ChemokinesCell-Mediated CytolysisCellsCellular InfiltrationChemotactic FactorsClinicalComplexCoronavirusEdemaEmployee StrikesEpithelial CellsEpitheliumEpitopesGasesHemagglutininHemorrhageHourImmune responseIn VitroIndividualInfectionInfiltrationInflammationInflammation MediatorsInflammatoryInfluenzaInfluenza HemagglutininInjuryInterferon Type IIJapanLungMediatingModelingMusNeutrophil InfiltrationOutcomeOxidantsPathologyPatternPneumoniaPopulationProcessProteolytic ProcessingReceptors, Tumor Necrosis Factor, Type IIRegulationRespiratory SystemRespiratory Tract InfectionsRespiratory tract structureRoleSeriesSeveritiesT-LymphocyteTNF geneTransgenic AnimalsTransgenic MiceTumor Necrosis Factor ReceptorViralViral AntigensVirusVirus Diseasesalveolar epitheliumcapillarychemokinedesigneosinophilimmunopathologyin vivointerstitiallung injurymacrophagemutantneutrophilrespiratory virusresponsetranscriptional coactivator p75tumor necrosis factor receptor 1A
中文摘要
描述(由申请方提供):呼吸道病毒(如流感病毒,特别是高致病性毒株)感染导致相当严重的肺部免疫病理学,其中很大一部分是由宿主T细胞应答引起的。这种肺损伤是此类感染临床结局的重要决定因素。我们已经开发了一种模型,以区分肺损伤,这是特别是由于CD 8 + T细胞识别肺上皮细胞上的病毒抗原和T细胞效应活性,从而触发,从这导致从病毒本身的细胞病变的影响。在这个提议中,我们的目标是扩展CD 8 + T细胞介导的损伤的表征,以剖析在流感肺炎的存在下与T细胞应答相关的复杂免疫病理过程。我们已经发现高度损伤和最小损伤的T细胞群体在将跨膜TNF加工成其可溶形式的阈值方面存在显著差异。作为原理的证明,我们已经开发了专门表达不可切割的跨膜形式的TNF的CD 8 + T细胞,并且已经观察到损伤潜力的显著降低。由这些T细胞触发的病理学显著的是显著的间质/隔膜细胞浸润,而没有肺泡腔的显著浸润,并且没有水肿或出血的证据。此外,虽然WT T细胞介导的损伤的特征在于在T细胞接合后的前12-24小时内PMN的瞬时积累,随后是巨噬细胞的急剧积累,但这种PMN流入在转移突变T细胞后并不明显。在突变T细胞的接受者中,气体交换仅轻度受损。我们假设跨膜TNF的处理阈值决定了CD 8 + T细胞识别后损伤的严重程度。我们进一步假设,以抗原特异性方式产生的可溶性TNF介导的增强损伤的机制是肺泡上皮细胞响应T细胞识别诱导中性粒细胞趋化因子表达,这导致早期和短暂的中性粒细胞募集到肺泡腔。这似乎是由TNF-R2(p75)介导的,导致ERK活化和Egr-1表达旺盛。我们将研究WT和突变型CD 8 + T细胞群,以及表达突变型TNF受体的各种转基因小鼠,以了解CD 8 + TNF加工成可溶性物质如何引发严重的肺损伤,以及调节机制。
英文摘要
DESCRIPTION (provided by applicant): Infection with respiratory viruses such as with influenza, particularly the highly pathogenic strains, results in considerable pulmonary immunopathology, a large component of which results from the host T cell responses. This lung injury is an important determinant of clinical outcome in such infections. We have developed a model to distinguish the lung injury that is specifically due to CD8+ T cell recognition of viral antigen on lung epithelium and T cell effector activities triggered thereby, from that which results from the cyopathic effects of the virus itself. In this proposal we aim to extend the characterization of CD8+ T cell mediated injury to dissect the complex immunopathologic processes associated with T cell responses in the presence of influenza pneumonia. We have found a significant difference between highly injurious and minimally injurious T cell populations in their threshold for processing transmembrane TNF to its soluble form. As a proof of principle, we have developed CD8+ T cells which exclusively express a non-cleavable transmembrane form of TNF, and have observed a marked reduction in injury potential. The pathology triggered by these T cells is remarkable for significant interstitial/septal cellular infiltration without significant infiltration of the alveolar space and without evidence of edema or hemorrhage. Furthermore, while WT T cell-mediated injury is characterized by transient accumulation of PMNs in the first 12-24 hours after T cell engagement, followed by dramatic accumulation of macrophages, this PMN influx was not evident after transfer of the mutant T cells. Gas exchange was only mildly impaired in recipients of the mutant T cells. We hypothesize that the threshold for processing of transmembrane TNF determines the severity of the injury after CD8+ T cell recognition. We further hypothesize that the mechanism of enhanced injury mediated by soluble TNF produced in an antigen-specific fashion is the induction of neutrophil chemoattractant expression by alveolar epithelial cells, in response to T cell recognition, which leads to early and transient neutrophil recruitment to the alveolar space. This appears to mediated by TNF-R2 (p75) leading to exuberant ERK activation and Egr-1 expression. We will study WT and mutant CD8+ T cell populations, and a variety of transgenic mice expressing mutant TNF receptors in order to understand how CD8+ TNF processing to the soluble species triggers severe lung injury, and the mechanisms of regulation.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Early events regulating post-viral immunopathology
-
批准号:9130393
-
项目类别:
-
资助金额:$40.5万
-
财政年份:2015
-
负责人:RICHARD I ENELOW
-
依托单位:
TYPE I INTERFERON REGULATION OF IMMUNOPATHOLOGY IN INFLUENZA PNEUMONIA
-
批准号:8168321
-
项目类别:
-
资助金额:$4.0万
-
财政年份:2010
-
负责人:RICHARD I ENELOW
-
依托单位:
Innate Regulation of CD8+ T Cell Effector Activites
-
批准号:7746104
-
项目类别:
-
资助金额:$39.84万
-
财政年份:2009
-
负责人:RICHARD I ENELOW
-
依托单位:
TYPE I INTERFERON REULATION OF IMMUNOPATHOLOGY IN INFLUENZA PNEUMONIA
-
批准号:7959996
-
项目类别:
-
资助金额:$23.99万
-
财政年份:2009
-
负责人:RICHARD I ENELOW
-
依托单位:
TYPE I INTERFERON REULATION OF IMMUNOPATHOLOGY IN INFLUENZA PNEUMONIA
-
批准号:7720753
-
项目类别:
-
资助金额:$23.51万
-
财政年份:2008
-
负责人:RICHARD I ENELOW
-
依托单位:
TNF Processing in Pulmonary Immunopathology
-
批准号:7494944
-
项目类别:
-
资助金额:$35.87万
-
财政年份:2007
-
负责人:RICHARD I ENELOW
-
依托单位:
TNF Processing in Pulmonary Immunopathology
-
批准号:7266760
-
项目类别:
-
资助金额:$36.54万
-
财政年份:2007
-
负责人:RICHARD I ENELOW
-
依托单位:
TNF Processing in Pulmonary Immunopathology
-
批准号:8136661
-
项目类别:
-
资助金额:$34.62万
-
财政年份:2007
-
负责人:RICHARD I ENELOW
-
依托单位:
TNF Processing in Pulmonary Immunopathology
-
批准号:7914286
-
项目类别:
-
资助金额:$34.97万
-
财政年份:2007
-
负责人:RICHARD I ENELOW
-
依托单位:
Interferon-gamma in Experimental Pulmonary Fibrosis
-
批准号:6629468
-
项目类别:
-
资助金额:$32.6万
-
财政年份:2002
-
负责人:RICHARD I ENELOW
-
依托单位:
Interferon-gamma in Experimental Pulmonary Fibrosis
-
批准号:6508378
-
项目类别:
-
资助金额:$37.0万
-
财政年份:2002
-
负责人:RICHARD I ENELOW
-
依托单位:
Interferon-gamma in Experimental Pulmonary Fibrosis
-
批准号:6901874
-
项目类别:
-
资助金额:$32.6万
-
财政年份:2002
-
负责人:RICHARD I ENELOW
-
依托单位:
Interferon-gamma in Experimental Pulmonary Fibrosis
-
批准号:6792157
-
项目类别:
-
资助金额:$32.6万
-
财政年份:2002
-
负责人:RICHARD I ENELOW
-
依托单位:
MECHANISMS OF CELL-MEDIATED LUNG INJURY
-
批准号:6389711
-
项目类别:
-
资助金额:$29.6万
-
财政年份:1997
-
负责人:RICHARD I ENELOW
-
依托单位:
MECHANISMS OF CELL-MEDIATED LUNG INJURY
-
批准号:6638482
-
项目类别:
-
资助金额:$22.82万
-
财政年份:1997
-
负责人:RICHARD I ENELOW
-
依托单位:
MECHANISMS OF CELL-MEDIATED LUNG INJURY
-
批准号:6537331
-
项目类别:
-
资助金额:$25.9万
-
财政年份:1997
-
负责人:RICHARD I ENELOW
-
依托单位:
MECHANISMS OF T CELL MEDIATED LUNG INJURY
-
批准号:6030837
-
项目类别:
-
资助金额:$11.34万
-
财政年份:1997
-
负责人:RICHARD I ENELOW
-
依托单位:
MECHANISMS OF T CELL MEDIATED LUNG INJURY
-
批准号:2735388
-
项目类别:
-
资助金额:$13.13万
-
财政年份:1997
-
负责人:RICHARD I ENELOW
-
依托单位:
MECHANISMS OF CELL-MEDIATED LUNG INJURY
-
批准号:6194838
-
项目类别:
-
资助金额:$29.6万
-
财政年份:1997
-
负责人:RICHARD I ENELOW
-
依托单位:
MECHANISMS OF T CELL MEDIATED LUNG INJURY
-
批准号:2383704
-
项目类别:
-
资助金额:$13.14万
-
财政年份:1997
-
负责人:RICHARD I ENELOW
-
依托单位:
海外基金